The following is a summary of “Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of ...

Tevimbra is under clinical development by BeiGene and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData, Phase III drugs for Hepatocellular Carcinoma have a 47% phase ...

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma ...

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the ...

The Barbara Ann Karmanos Cancer Institute in Detroit says the new TheraBionic P1 device, an FDA-approved, at-home treatment, ...

It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy ...

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III ...

This is a significant departure from traditional cancer treatments that rely on killing cancer cells, often leading to severe ...

A phase 3 clinical trial suggests that stereotactic body radiation therapy prior to systemic treatment may improve survival ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

The most frequent liver cancers are hepatocellular carcinoma and hepatoblastoma (formed by immature liver cells). The molecular landscape of Fibrolamellar Hepatocellular Carcinoma (FLC), a rare ...